Novartis | NVS - Net Income



Novartis reported $4.04B in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Amgen USD 1.43B 298M Jun/2025
AstraZeneca USD 2.45B 466M Jun/2025
Bausch Health Companies USD 148M 206M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Canopy Growth CAD -41530000 80.37M Jun/2025
Corcept Therapeutics USD 35.15M 14.6M Jun/2025
Drreddys Laboratories INR 14.18B 45M Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
GlaxoSmithKline GBP 1.44B 181M Jun/2025
Glaxosmithkline GBP 1.44B 1.03B Jun/2025
J&J USD 5.54B 5.46B Jun/2025
Merck USD 4.43B 652M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Novartis USD 4.04B 1.22B Jun/2025
Pacira USD -4847000 9.66M Jun/2025
Perrigo USD -8400000 2M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Prestige Brands USD 61.78M 11.65M Jun/2025
Roche Holding CHF 1.01B 2.12B Dec/2024
Sanofi EUR 3.94B 2.07B Jun/2025
Sanofi EUR 3.94B 3.44B Jun/2025
Supernus Pharmaceuticals USD 22.5M 34.33M Jun/2025
Zoetis USD 718M 87M Jun/2025